Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Matthias Graf von der Schulenburg"'
Autor:
Victoria W. Dayer, Michael F. Drummond, Omar Dabbous, Mondher Toumi, Peter Neumann, Sean Tunis, Nelson Teich, Shadi Saleh, Ulf Persson, Johann-Matthias Graf von der Schulenburg, Daniel C. Malone, Tay Salimullah, Sean D. Sullivan
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-12 (2024)
Abstract Health technology assessment (HTA) decisions for pharmaceuticals are complex and evolving. New rare disease treatments are often approved more quickly through accelerated approval schemes, creating more uncertainties about clinical evidence
Externí odkaz:
https://doaj.org/article/18f7fcfcb90a4c4685fa9f6e8e16039b
Autor:
Su-Jong Kim-Dorner, Torben Schmidt, Alexander Kuhlmann, Johann-Matthias Graf von der Schulenburg, Tobias Welte, Heidrun Lingner
Publikováno v:
npj Primary Care Respiratory Medicine, Vol 32, Iss 1, Pp 1-12 (2022)
Abstract Chronic obstructive pulmonary disease (COPD) is a debilitating medical condition often accompanied by multiple chronic conditions. COPD is more frequent among older adults and affects both genders. The aim of the current cross-sectional surv
Externí odkaz:
https://doaj.org/article/2f729f2e33e643cdbc2448120b9d5136
Autor:
Jan Zeidler, Uwe Tegtbur, Sven Haufe, Hedwig Theda Boeck, Sebastian Häckl, Johanna Boyen, Momme Kück, Clara Catharina van Rhee, Johann-Matthias Graf von der Schulenburg, Torben Schmidt, Heiko Johannsen, Dennis Holzwart, Armin Koch
Publikováno v:
BMJ Open Sport & Exercise Medicine, Vol 8, Iss 4 (2022)
Background Electrically assisted bicycles (e-bikes) have become increasingly popular and may facilitate active commuting and recreational cycling.Objective To evaluate the physical activity levels and usage characteristics of e-bikers and conventiona
Externí odkaz:
https://doaj.org/article/109f8784884441e8ab786aa06d5d0d0c
Autor:
Johannes Boettcher, Bonnie Filter, Jonas Denecke, Amra Hot, Anne Daubmann, Antonia Zapf, Karl Wegscheider, Jan Zeidler, J.-Matthias Graf von der Schulenburg, Monika Bullinger, Miriam Rassenhofer, Michael Schulte-Markwort, Silke Wiegand-Grefe
Publikováno v:
BMC Family Practice, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Families of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families car
Externí odkaz:
https://doaj.org/article/e40efbedc6d7412e871242ec4db6b92a
Autor:
Svenja Litzkendorf, Martin Frank, Ana Babac, Daniel Rosenfeldt, Franziska Schauer, Tobias Hartz, J.-Matthias Graf von der Schulenburg
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Finding reliable information on one of more than 7000 rare diseases is a major challenge for those affected. Since rare diseases are defined only by the prevalence criterion, a multitude of heterogeneous diseases are included. Com
Externí odkaz:
https://doaj.org/article/20f799d1b02744f896a286975b6c5e8b
Publikováno v:
Health Economics Review, Vol 9, Iss 1, Pp 1-17 (2019)
Abstract Background Since the implementation of the Regulation on Patient Integration (2003), the Act on the Reorganization of the Pharmaceutical Market (2011), and the Patient Rights Law (2013), the inclusion of patient perspectives has been further
Externí odkaz:
https://doaj.org/article/a02c93154c8f4c40afc9cbbe9ba45d14
Insurance today is a global economic colossus and a fixture in the developed countries of the world. Dependant upon a considerable dose of moral exhortation and enlightened appeal, the insurance industry has become a pervasive agent of social and eco
Autor:
Mondher Toumi, Omar Dabbous, Samuel Aballéa, Michael F. Drummond, Johann-Matthias Graf von der Schulenburg, Daniel C. Malone, Peter J. Neumann, Sean D. Sullivan, Sean Tunis
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 23:483-497
Autor:
Ana Babac, Verena von Friedrichs, Svenja Litzkendorf, Jan Zeidler, Kathrin Damm, J.-Matthias Graf von der Schulenburg
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-17 (2019)
Abstract Background Many European countries have recently implemented national rare disease plans. Although the network is strengthening, especially on the macro and meso levels, patients still go a long way through healthcare systems, with many heal
Externí odkaz:
https://doaj.org/article/6b3ba6c61d6844ed9cedb654924d13e4
Autor:
Thomas R. Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J.-Matthias Graf von der Schulenburg, Volker E. Amelung, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from th
Externí odkaz:
https://doaj.org/article/b0233d39cbbf4519bd29290918586e0e